MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Preliminary Evidence of Single-Agent Activity in First-in-Human Clinical

  MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Preliminary Evidence of
            Single-Agent Activity in First-in-Human Clinical Study

Extension of Progression-Free Survival Observed Compared to Last Prior Therapy

PR Newswire

SAN DIEGO, Oct. 21, 2013

SAN DIEGO, Oct. 21, 2013 /PRNewswire/ --MEI Pharma, Inc. (Nasdaq: MEIP), an
oncology company focused on the clinical development of novel therapies for
cancer, announced results from a Phase I first-in-human, single-agent clinical
study of its investigational mitochondrial inhibitor drug candidate, ME-344,
in patients with refractory solid tumors. The results, presented yesterday at
the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer
Therapeutics in Boston, indicated that five of 21 evaluable patients treated
with ME-344 experienced progression free survival (34 to 61+ weeks) that was
at least twice the duration of their last prior treatment before entry into
the study.


In addition, the presentation highlighted that one of these 5 patients, a
heavily pre-treated patient with small cell lung cancer, achieved a confirmed
partial response. The patient received his first treatment of ME-344 in August
2012 and has now been on study for more than 61 weeks. His June 2013 scans
showed a decrease of 32% in target lesions, which was confirmed in his most
recent scans (August 2013). This patient and three others remain on study and
continue weekly dosing.

"The observed radiographic partial response is promising, particularly in such
a difficult-to-treat disease as small cell lung cancer," said presenter and
co-investigator Jeffrey R. Infante, MD, Director, Drug Development at Sarah
Cannon Research Institute and Tennessee Oncology. "In addition to tumor
shrinkage, this patient has also demonstrated symptomatic improvement while on
study, including decreased cough, shortness of breath and improved performance
status. The results of this single agent Phase I study are encouraging and
further clinical development of ME-344 is warranted."

A copy of yesterday's poster presentation, entitled "ME-344, a novel
mitochondrial oxygenase inhibitor: Results from a first-in-human Phase I
study," is now available at

ME-344 was generally well tolerated at doses equal to or less than 10 mg/kg
delivered on a weekly schedule for extended durations. Dose limiting
toxicities were observed at both the 15 and 20 mg/kg dose levels, consisting
primarily of Grade 3 peripheral neuropathy. Other medically significant
adverse events observed in single patients included angina and QTc
prolongation at the 10 mg/kg dose.

"We are encouraged by the results from this first-in-human study of ME-344,"
said Robert D. Mass, MD, Chief Medical Officer of MEI Pharma. "Not only did
the trial show evidence of clinical activity, but the primary dose limiting
toxicity was consistent with the proposed mechanism of action of ME-344,
namely mitochondrial inhibition, suggesting on-target activity. Based on these
findings, we are now actively preparing for a Phase Ib clinical trial of
ME-344 in combination with Hycamtin^® (topotecan) in small cell lung cancer
and ovarian cancer, which we expect to initiate during the second quarter of

The Phase Ib trial will be designed to evaluate the safety and tolerability of
ME-344 in combination with Hycamtin^® in a total of 45 patients with either
small cell lung cancer or ovarian cancer. Hycamtin^® is a chemotherapy
approved by the U.S. Food & Drug Administration for the treatment of small
cell lung cancer and ovarian cancer, as well as cervical cancer.

About ME-344
ME-344 is MEI Pharma's isoflavone-derived mitochondrial inhibitor drug
candidate. In preclinical studies, ME-344 has been shown to cause
caspase-independent cell death in multiple human tumor cell lines, including
ovarian cancer stem cells, by interfering with mitochondrial energy
generation. In April 2013, Ayesha Alvero, MD, Yale University School of
Medicine, presented data at the American Association for Cancer Research
Annual Meeting showing the ability of ME-344 to decrease tumor burden and
delay recurrence in a pre-clinical in vivo model of recurrent epithelial
ovarian cancer, the most lethal of all gynecologic malignancies.

MEI Pharma owns exclusive worldwide rights to ME-344.

About MEI Pharma
MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused
on the clinical development of novel therapies for cancer. The Company's lead
drug candidate is Pracinostat, a potential best-in-class, oral HDAC inhibitor
being developed for advanced hematologic diseases, such as myelodysplastic
syndrome (MDS) and acute myeloid leukemia (AML). The Company initiated a
randomized, placebo-controlled Phase II trial of Pracinostat in combination
with Vidaza (azacitidine) in patients with previously untreated MDS in June
2013. An open-label Phase II trial of Pracinostat in combination with Vidaza
in elderly patients with AML who are unsuitable for intensive chemotherapy is
expected to initiate in the fall of 2013. In September 2013, the Company
further expanded its pipeline of drug candidates with the acquisition of
PWT143, a highly selective PI3-kinase delta inhibitor. For more information,
go to

About Sarah Cannon Research Institute

Sarah Cannon Research Institute (SCRI) is a global strategic research
organization focusing on advancing therapies for patients. It is one of the
largest clinical research programs, conducting community-based clinical trials
in oncology and cardiology through affiliations with a network of more than
700 physicians in the United States and United Kingdom. Additionally, SCRI
offers management, regulatory and other research support services to drug
development sponsors and strategic investigator sites. For more information,
please visit

Under U.S. law, a new drug cannot be marketed until it has been investigated
in clinical trials and approved by the FDA as being safe and effective for the
intended use. Statements included in this press release that are not
historical in nature are "forward-looking statements" within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ materially
from those contained in the forward-looking statements, which are based on
management's current expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to successfully
commercialize our product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such approval, of our product
candidates; uncertainties or differences in interpretation in clinical trial
results; our inability to maintain or enter into, and the risks resulting from
our dependence upon, collaboration or contractual arrangements necessary for
the development, manufacture, commercialization, marketing, sales and
distribution of any products; competitive factors; our inability to protect
our patents or proprietary rights and obtain necessary rights to third party
patents and intellectual property to operate our business; our inability to
operate our business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to gain
market acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice;
and one-time events. We do not intend to update any of these factors or to
publicly announce the results of any revisions to these forward-looking

SOURCE MEI Pharma, Inc.

Contact: Pete De Spain, Sr. Director, Investor Relations & Corporate
Communications, +1-858-792-3729,
Press spacebar to pause and continue. Press esc to stop.